DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/57h2sv/top_472_biotechnol) has announced the addition of the "Top 472 Biotechnology (Pharmaceuticals) (Global)" report to their offering.

This report is an in-depth financial evaluation of the GlobalBiotechnology (Pharmaceuticals). Using the unique Plimsoll method of analysis, each of the top 472 companies included is individually assessed and ranked against each other and compared to industry averages.Using the most up-to-date financial information available, the two-page per company analysis provides detailed financial analysis for each organisation. The following are some of the key findings of this new report:

- 210 of the 472 companies analysed have been rated as Danger

- 126 companies are ripe for takeover

- 300 companies achieved greater than 10% increase in sales last year.

- 196 companies made a pre-tax loss.

- 145 companies saw sales fall last year.

Our analysis gives you this unrivalled market and company intelligence using a simple graphical, numeric and model. Each company is individually analysed in both the company's own currency, and USD ($) for ease of use. These individual analyses highlight a company's strengths and weaknesses instantly.

Along with individual company information, this report also contains a comprehensive study of the market, based on the companies analysed. This key information includes:

Go here to read the rest:
Research and Markets: Top 472 Biotechnology (Pharmaceuticals) (Global)